HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Characterization of mitotane (o,p′-DDD) – cyclodextrin inclusion complexes: Phase-solubility method and NMR

Abstract : Mitotane (o,p′-dichlorodimethyl dichloroethane [o,p′-DDD]) is used for the treatment of adrenocortical cancer and occasionally Cushing’s syndrome. This drug is very poorly soluble in water, and following oral administration, approximately 60% of the dose is recovered in the feces unaltered. The preparation of a soluble formulation (i.e. by complexation with cyclodextrins) with improved bioavailability is the aim of this work. The inclusion of mitotane in methyl-ß-cyclodextrins was studied using both phase-solubility methods and NMR experiments. To elucidate the inclusion mechanism, o,p′-DDD was compared to its regioisomer (i.e. p,p′-DDD). It was demonstrated that two dimethyl-ß-cyclodextrins (DMßCD) can complex with the aromatic rings. From the phase-solubility diagrams, we observe that both cases are very different: K1:1 is between 37 000 and 85 000mol.l−1, whereas K1:2 is between 5.3 and 32mol.l−1. The NMR experiments confirmed the inclusion but it also gave an insight into the kinetics of the dissociation: the ortho-chloro moiety is in slow exchange on the NMR time scale, whereas the para-chloro moiety is in fast exchange rate.
Document type :
Journal articles
Complete list of metadata

https://hal.univ-lorraine.fr/hal-01290439
Contributor : Cithefor Ul Connect in order to contact the contributor
Submitted on : Friday, March 18, 2016 - 10:39:18 AM
Last modification on : Tuesday, November 16, 2021 - 3:04:05 PM

Identifiers

Collections

Citation

R. Alfonsi, D. Attivi, A. Astier, Marie Socha, S. Morice, et al.. Characterization of mitotane (o,p′-DDD) – cyclodextrin inclusion complexes: Phase-solubility method and NMR. Annales Pharmaceutiques Françaises, Elsevier Masson, 2013, 71 (3), pp.186-92. ⟨10.1016/j.pharma.2013.02.001⟩. ⟨hal-01290439⟩

Share

Metrics

Record views

66